Applying New Stem Cell Science to Reboot the Immune System

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. By creating a platform focused on key areas of transplant medicine, Magenta Therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit.

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

May 18, 2017
Magenta Therapeutics Selected as “Hottest Early Stage Startup” in Healthcare in New England Venture Capital Association’s 2017 NEVY Awards

May 10, 2017
Magenta Therapeutics Announces New Clinical Data on its Lead Expansion Clinical Program, MGTA-456, Presented at American Society of Gene and Cell Therapy Annual Meeting

May 2, 2017
Magenta Therapeutics Advances Stem Cell Transplantation Strategy with $50 Million Series B Financing, Licensing of Clinical-Stage Stem Cell Expansion Program and Strategic Partnership with Be The Match BioTherapies

Read More News

Associated Team Members

Alexis Borisy